<DOC>
	<DOCNO>NCT01469598</DOCNO>
	<brief_summary>Gemcitabine novel analog nucleoside deoxycytidine act via inhibition DNA synthesis.Docetaxel semisynthetic taxane promotes microtubule assembly inhibit microtubule depolymerization . In study , patient receive gemcitabine 900 mg/m2 day 1 8 plus docetaxel 100 mg/m2 day 8 G-CSF support every 3 week .</brief_summary>
	<brief_title>Study Docetaxel Gemcitabine Metastatic Esophageal Squamous Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm metastatic , recurrent esophageal squamous cell carcinoma Age &gt; 18 year ECOG performance status 0 2 At least one measurable lesion ( ) RECIST 1.1 criterion Life expectancy ≥ 3 month At least one cytotoxic chemotherapy regimen ( adjuvant chemotherapy consider one regimen administer within 6 month date study entry ) ( upto three prior regimen allow ) Prior radiotherapy must complete 2 week study entry . Adequate bone marrow function ( ≥ ANC 1,500/ul , ≥ platelet 100,000/ul , ≥ Hemoglobin 9.0 g/dl ) Adequate renal function ( ≤ serum creatinine 1.5 mg/dl CCr ≥ 50 ml/min ) Adequate liver function ( ≤ serum bilirubin 1.5 mg/dl , ≤ AST/ALT x 3 upper normal limit ) Written informed consent Evidence serious gastrointestinal bleeding Serious pulmonary conditions/illness ( e.g . chronic lung disease hypoxemia ) Serious metabolic disease severe noncompensated diabetes mellitus History significant neurologic psychiatric disorder Serious uncontrolled intercurrent infection , serious uncontrolled concomitant disease Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>